Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurotech International ( (AU:NTI) ) just unveiled an announcement.
Neurotech International Limited held its Annual General Meeting, where all resolutions were determined by a poll. The meeting’s outcomes, including the adoption of the remuneration report and re-election of Mark Davies, were carried successfully, indicating strong shareholder support. This meeting underscores Neurotech’s stable governance and continued focus on advancing its clinical programs, potentially enhancing its position in the biopharmaceutical industry.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical development company focusing on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has conducted successful Phase II/III clinical trials in Autism Spectrum Disorder (ASD) and Phase I/II trials in ASD, PANDAS/PANS, and Rett Syndrome, with plans for a trial in spastic cerebral palsy.
Average Trading Volume: 1,392,257
Technical Sentiment Signal: Sell
Current Market Cap: A$16.79M
For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.